Pfizer director granted 1,852.614 phantom units
SMITH JAMES C reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
SMITH JAMES C reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director James C. Smith received a grant of 1,852.614 Phantom Stock Units tied to Pfizer common stock. The units were awarded at a reference price of $24.2900 per unit and increase his phantom stock balance to 182,886.001 units.
According to the disclosure, these units represent deferred director compensation, including dividend equivalents, and will be settled in cash or common stock at his election after he retires from the Board of Directors. This is a compensation-related, non‑market transaction rather than an open‑market purchase or sale of Pfizer shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Phantom Stock Units | 1,852.614 | $24.29 | $45K |
Footnotes (2)
- F1. Each unit represents one phantom share of common stock.
- F2. These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.
Key Figures
Key Terms
Phantom Stock Units financial
deferred director's compensation financial
dividend equivalents financial
underlying security financial
AI-generated analysis. How Rhea-AI works. Not financial advice.